Effect of Entacapone Plus Levodopa/Carbidopa on Anxiety, Depression, and Quality of Life in Patients with Parkinson Disease
10.12007/j.issn.0258-4646.2019.02.016
- VernacularTitle:恩他卡朋与左旋多巴/卡比多巴联合治疗对帕金森病患者焦虑、抑郁及生活质量的影响
- Author:
Huagang LI
1
;
Jinsong XIAO
;
Hong ZHU
Author Information
1. 武汉大学中南医院神经内科
- Keywords:
entacapone;
levodopa/carbidopa;
Parkinson's disease;
anxiety;
depression;
quality of life
- From:
Journal of China Medical University
2019;48(2):164-169
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of levodopa/carbidopa plus entacapone (LCE) and levodopa/carbidopa (LC) on anxiety, depression, and quality of life (QOL) between patients with Parkinson disease (PD). Methods In total, 120 patients with idiopathic PD were enrolled in this trial and randomized into the experimental (LCE) and control (LC) groups in a 1∶1 ratio to receive treatment for12 weeks. The Hamilton anxiety scale score (HAMA), Hamilton depression scale score (HAMD), 39-item PD QOL questionnaire score (PDQ-39), Unified PD rating scale score (UPDRS), "on" time (h/d), and "off" time (h/d) were measured at each visit (baseline 0, 4, 8, and 12 weeks). Results At the end point (12 weeks), the decrease in the HAMA score from baseline was higher in the LCE group compared with that in the LC group (3.6±1.3, 95％ CI:3.3-3.9 vs 1.3±0.7, 95％ CI:1.1-1.5, P＜0.001), as well as the HAMD score (5.2±1.9, 95％ CI:4.7-5.7 vs 1.2±0.7, 95％ CI:1.0-1.4, P ＜0.001). Similarly, the changes in the PDQ-39 score were evaluated, and the change was compared between the LCE group and the LC group (14.1±7.8, 95％ CI:12.1-16.1 vs 6.9±4.2, 95％ CI:5.8-8.0, P＜0.001). In addition, the LCE group presented better improvement in the UPDRS score (Ⅰ-Ⅳ), "on" time, and "off" time from the baseline than that in the LC group (P ＜ 0.05). Conclusion Entacapone combined with levodopa/carbidopa could significantly improve anxiety, depression, and QOL in patients with PD experiencing wearing-off.
